147650-54-2

Basic information

• Product Name: 3,4-O-Isopropylidene ClindaMycin
• Synonyms: 3,4-O-Isopropylidene ClindaMycin
• CAS NO: 147650-54-2
• Molecular Formula: C21H37ClN2O5S
• Molecular Weight: 465.04688
• Product Categories: Carbohydrates & Derivatives;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Phosphorylating and Phosphitylating Agents;Carbohydrates & Derivatives, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals, Phosphorylating and Phosphitylating Agents
• Mol File: 147650-54-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 145-147.5 °C
• Boiling Point: 630.9±55.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly, Sonicated), Methanol (Slightly)
• PKA: 12.66±0.70(Predicted)
• CAS DataBase Reference: 3,4-O-Isopropylidene ClindaMycin(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-O-Isopropylidene ClindaMycin(147650-54-2)
• EPA Substance Registry System: 3,4-O-Isopropylidene ClindaMycin(147650-54-2)

Safety Data

• Hazardous Substances Data: 147650-54-2(Hazardous Substances Data)

Usage

Chemical Properties

3,4-O-Isopropylidene ClindaMycin is Yellow Solid

Uses

Different sources of media describe the Uses of 147650-54-2 differently. You can refer to the following data:
1. Clindamycin (C580000) derivative. Used in the preparation of Clindamycin impurities.
2. 3,4-O-Isopropylidene ClindaMycin is used in the preparation of Clindamycin impurities.

Upstream product

• 17431-55-9 clindamycin hydrochloride 
• 77-76-9 2,2-dimethoxy-propane 
• 16684-06-3 clindamycin 
• 122-51-0 orthoformic acid triethyl ester 
• 859-18-7 lincomycin hydrochloride 
• 67-64-1 acetone 
• 21462-39-5 clindamycin hydrochloride 

Relevant articles and documents

Synthesis process of clindamycin palmitate hydrochloride

The invention provides a synthesis process of clindamycin palmitate hydrochloride. Clindamycin hydrochloride as a parent and pyridine are mixed and heated, 2,2-dimethoxypropane is added, a reaction is performed sufficiently, and the residual pyridine and 2,2-dimethoxypropane are distilled off after the reaction is ended to reduce the generation of byproducts; then acetone is added to separate out solids, water and sodium hydroxide are added to obtain 3,4-o-isopropylidene-clindamycin with few impurities, and palmitoyl chloride and the 3,4-o-isopropylidene-clindamycin are mixed at a certain temperature and fully react, thereby facilitating the subsequent generation of high-purity products and increasing the target product content; and then a protecting group is removed by acidolysis, washing is performed with a detergent and water to remove the impurities, sodium sulfate is added to remove the water and the residual detergent, and finally hydrochloric acid is added to treat viscous liquid at a certain temperature, thereby reducing the production of byproducts and increasing the product yield.

CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS

The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA)m-X-(L)n; (ii) [(AFA)m′-X]p-L; (iii) AFA-[X-(L)n′]q; or (iv) (AFA)m″-X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.